Healthcare Active Runners: Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) by Mallinckrodt plc (NYSE: MNK). On February 11, 2014, the two companies announced the signing of a definitive agreement pursuant to which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence stock for $14.00 per share in cash. Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) stock opened at $13.98 in last trading session, and closed at $14.00, trading in the range of $13.96 – $14.03. The stock showed a positive weekly performance of 30.60%.

RheoSense, Inc., the leading manufacturer of viscometers, is pleased to announce another milestone reached in partnership with Pfizer Inc. (NYSE:PFE). With a strategically collaborative effort between Pfizer and RheoSense, it is our pleasure to have placed the 10th m-VROC unit with Pfizer. Pfizer Inc. (NYSE:PFE) shares closed at $31.88 on last trade day, by gaining 1.30%. Stock 52 week range is $26.81 – 32.50. Company’s market capitalization is $206.62 billion.

Merck & Co (NYSE:MRK) Director Peter C. Wendell sold 5,000 shares of the stock on the open market in a transaction dated Monday, February 10th. The stock was sold at an average price of $54.44, for a total transaction of $272,200.00. Following the completion of the sale, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $54,440. Merck & Co., Inc. (NYSE:MRK) stock advanced 1.48% and finished the last session at $55.70. The EPS of the stock remained 1.48. Company’s market capitalization is $163.01 billion.

Research analysts at Credit Suisse set a $8.00 price target on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) stock in a report released on Friday, Analyst RN reports. Credit Suisse’s target price suggests a potential downside of 1.60% from the stock’s previous close. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened at $8.14 in last trading session and closed at $8.16. The 52 week range of the stock is $2.15 – $23.00 and the day range was $8.05 – $8.35.